Literature DB >> 21628081

Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.

Fran Supek1, Tatjana Šumanovac Ramljak, Marko Marjanović, Maja Buljubašić, Goran Kragol, Nataša Ilić, Tomislav Smuc, Davor Zahradka, Kata Mlinarić-Majerski, Marijeta Kralj.   

Abstract

18-crown-6 ethers are known to exert their biological activity by transporting K(+) ions across cell membranes. Using non-linear Support Vector Machines regression, we searched for structural features that influence antiproliferative activity in a diverse set of 19 known oxa-, monoaza- and diaza-18-crown-6 ethers. Here, we show that the logP of the molecule is the most important molecular descriptor, among ∼1300 tested descriptors, in determining biological potency (R(2)(cv) = 0.704). The optimal logP was at 5.5 (Ghose-Crippen ALOGP estimate) while both higher and lower values were detrimental to biological potency. After controlling for logP, we found that the antiproliferative activity of the molecule was generally not affected by side chain length, molecular symmetry, or presence of side chain amide links. To validate this QSAR model, we synthesized six novel, highly lipophilic diaza-18-crown-6 derivatives with adamantane moieties attached to the side arms. These compounds have near-optimal logP values and consequently exhibit strong growth inhibition in various human cancer cell lines and a bacterial system. The bioactivities of different diaza-18-crown-6 analogs in Bacillus subtilis and cancer cells were correlated, suggesting conserved molecular features may be mediating the cytotoxic response. We conclude that relying primarily on the logP is a sensible strategy in preparing future 18-crown-6 analogs with optimized biological activity.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628081     DOI: 10.1016/j.ejmech.2011.05.009

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  In vitro antiproliferative study of novel adamantyl pyridin-4-ones.

Authors:  V Petrović Peroković; Ž Car; T Opačak-Bernardi; I Martin-Kleiner; M Kralj; S Tomić
Journal:  Mol Divers       Date:  2017-07-10       Impact factor: 2.943

2.  Adamantyl pyran-4-one derivatives and their in vitro antiproliferative activity.

Authors:  Vesna Petrović Peroković; Željka Car; Andrea Usenik; Teuta Opačak-Bernardi; Andrea Jurić; Srđanka Tomić
Journal:  Mol Divers       Date:  2019-04-05       Impact factor: 2.943

3.  Interaction of crown ethers with the ABCG2 transporter and their implication for multidrug resistance reversal.

Authors:  Marija Mioč; Ágnes Telbisz; Katarina Radman; Branimir Bertoša; Tatjana Šumanovac; Balázs Sarkadi; Marijeta Kralj
Journal:  Histochem Cell Biol       Date:  2022-06-01       Impact factor: 2.531

4.  Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells.

Authors:  Iva Guberović; Marko Marjanović; Marija Mioč; Katja Ester; Irena Martin-Kleiner; Tatjana Šumanovac Ramljak; Kata Mlinarić-Majerski; Marijeta Kralj
Journal:  Sci Rep       Date:  2018-09-27       Impact factor: 4.379

5.  Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells.

Authors:  Monika Hudáčová; Slávka Hamuľaková; Eva Konkoľová; Rastislav Jendželovský; Jana Vargová; Juraj Ševc; Peter Fedoročko; Ondrej Soukup; Jana Janočková; Veronika Ihnatova; Tomáš Kučera; Petr Bzonek; Nikola Novakova; Daniel Jun; Lucie Junova; Jan Korábečný; Kamil Kuča; Mária Kožurková
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

6.  p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines.

Authors:  Saori Fukushi; Hironori Yoshino; Atsushi Yoshizawa; Ikuo Kashiwakura
Journal:  BMC Cancer       Date:  2016-07-25       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.